A total of 360 T2D patients with eGFR ≥ 30 mL/min/1.73 m2 and a urinary albumin-to-creatinine ratio (UACR) 30–3000 mg/g were randomized to receive linagliptin (n = 182) or placebo (n = 178) for 24 weeks. The gene discussed is ALB; the disease is type 2 diabetes mellitus.